Company intelligence / Profile preview
Chengdu Yunke Pharmaceutical
Chengdu, Sichuan Sheng/Sichuan Province, Chinayunke.cn ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Chengdu Yunke Pharmaceutical is a leading Chinese radiopharmaceutical company, the first in China to pass GMP certification for nuclide drugs. Its key products include Iodine‑125 seed sources for tumor brachytherapy and Technetium(99Tc) methylenediphosphonate (Yunke Injection), approved for rheumatoid arthritis and studied in psoriatic arthritis. The company’s clinical results include completed Phase 4 studies and multiple approved products in China.
- Therapeutic areas
- OncologyRheumatologyImmunology
- Modalities
- Therapeutic radiopharmaceuticalsSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Chengdu Yunke Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Yunke Pharmaceutical.